Tuesday, June 8, 2004

ASCO 2004 ASCO 2004

OncoLink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.


Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 Multicentre Trial
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN):  Results of a phase II study.
Changing patterns of practice in the management of nasopharynx carcinoma (NPC): Analysis of the National Cancer Database (NCDB)
Phase III randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety
Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck
Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy

News
No new evidence found to support reversal of USPSTF 2004 recommendation against screening

Sep 22, 2010 - No new evidence has emerged warranting a change in the U.S. Preventive Services Task Force's 2004 conclusion that screening asymptomatic men for testicular cancer is unlikely to offer benefits over clinical detection, according to a literature review in the Sept. 21 issue of the Annals of Internal Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More